Abbott Laboratories (ABT) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $89.76 (-1.12%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Danielle Antalffy | UBS | $158.00 | +76.0% |
| Jan 29, 2026 | Ilya Zubkov | Loop Capital Markets | $120.00 | +33.7% |
| Jan 23, 2026 | Anthony Petrone | Mizuho Securities | $125.00 | +39.3% |
| Jan 23, 2026 | Larry Biegelsen | Wells Fargo | $122.00 | +35.9% |
| Jan 9, 2026 | Lee Hambright | Bernstein | $154.00 | +71.6% |
| Dec 22, 2025 | Marie Thibault | BTIG | $145.00 | +61.5% |
| Jul 15, 2025 | Shagun Singh | RBC Capital | $147.00 | +63.8% |
| Apr 15, 2025 | Shagun Singh | RBC Capital | $140.00 | +56.0% |
| Jan 8, 2025 | Lee Hambright | Bernstein | $135.00 | +50.4% |
| Oct 17, 2024 | Adam Maeder | Piper Sandler | $133.00 | +48.2% |
| Oct 17, 2024 | Lee Hambright | Bernstein | $138.00 | +53.7% |
| Oct 16, 2024 | Matthew Taylor | Jefferies | $125.00 | +39.3% |
| Oct 16, 2024 | Vijay Kumar | Evercore ISI | $128.00 | +42.6% |
| Oct 16, 2024 | Marie Thibault | BTIG | $139.00 | +54.9% |
| Oct 8, 2024 | Charles Minervino | Susquehanna | $120.00 | +33.7% |
| Oct 8, 2024 | Suraj Kalia | Oppenheimer | $130.00 | +44.8% |
| Oct 8, 2024 | Shagun Singh | RBC Capital | $130.00 | +44.8% |
| Sep 19, 2024 | Scott Fortune | Roth Capital | $24.01 | -73.3% |
| Sep 19, 2024 | Jonathan Atkin | RBC Capital | $165.65 | +84.5% |
| Sep 19, 2024 | Adam Maeder | Piper Sandler | $131.00 | +45.9% |
Top Analysts Covering ABT
ABT vs Sector & Market
| Metric | ABT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.24 | 2.41 |
| Analyst Count | 28 | 8 | 18 |
| Target Upside | +43.4% | +1150.2% | +14.9% |
| P/E Ratio | 25.00 | 6.85 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $50.24B | $50.31B | $50.43B | 19 |
| 2027-03-31 | $12.65B | $12.79B | $12.91B | 7 |
| 2027-06-30 | $13.36B | $13.51B | $13.63B | 7 |
| 2027-09-30 | $13.97B | $14.12B | $14.25B | 7 |
| 2027-12-31 | $14.39B | $14.54B | $14.68B | 7 |
| 2028-03-31 | $13.65B | $13.79B | $13.92B | 6 |
| 2028-06-30 | $14.32B | $14.47B | $14.61B | 6 |
| 2028-09-30 | $14.96B | $15.12B | $15.27B | 6 |
| 2028-12-31 | $15.39B | $15.56B | $15.71B | 6 |
| 2029-12-31 | $60.65B | $62.65B | $63.09B | 11 |
| 2030-12-31 | $66.07B | $68.25B | $68.72B | 9 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $5.47 | $5.48 | $5.50 | 16 |
| 2027-03-31 | $1.27 | $1.29 | $1.30 | 6 |
| 2027-06-30 | $1.42 | $1.44 | $1.46 | 6 |
| 2027-09-30 | $1.56 | $1.58 | $1.60 | 6 |
| 2027-12-31 | $1.72 | $1.74 | $1.76 | 6 |
| 2028-03-31 | $1.47 | $1.49 | $1.51 | 7 |
| 2028-06-30 | $1.60 | $1.62 | $1.64 | 7 |
| 2028-09-30 | $1.73 | $1.75 | $1.77 | 7 |
| 2028-12-31 | $1.86 | $1.89 | $1.91 | 7 |
| 2029-12-31 | $7.23 | $7.55 | $7.61 | 3 |
| 2030-12-31 | $8.01 | $8.36 | $8.43 | 3 |
Frequently Asked Questions
What is the analyst consensus for ABT?
The consensus among 28 analysts covering Abbott Laboratories (ABT) is Buy with an average price target of $137.67.
What is the highest price target for ABT?
The highest price target for ABT is $165.65, set by Jonathan Atkin at RBC Capital on 2024-09-19.
What is the lowest price target for ABT?
The lowest price target for ABT is $24.01, set by Scott Fortune at Roth Capital on 2024-09-19.
How many analysts cover ABT?
28 analysts have issued ratings for Abbott Laboratories in the past 12 months.
Is ABT a buy or sell right now?
Based on 28 analyst ratings, ABT has a consensus rating of Buy (2.00/5) with a +43.4% upside to the consensus target of $137.67.
What are the earnings estimates for ABT?
Analysts estimate ABT will report EPS of $5.48 for the period ending 2026-12-31, with revenue estimated at $50.31B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.